Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2026.1772315 Correction Correction: Improving the therapeutic efficacy of sorafenib for hepatocellular carcinoma by repurposing disulfiram ZhangGong 1 2 † Writing – review & editing WangYufeng 1 3 † Writing – original draft Writing – review & editing FuchsBryan C. 1 Writing – review & editing GuoWei 1 Writing – review & editing DrumDavid L. 1 Writing – review & editing ErstadDerek J. 1 Writing – review & editing ShiBaomin 3 Writing – review & editing DeLeoAlbert B. 1 Writing – review & editing ZhengHui 4 Writing – review & editing CaiLei 1 Writing – review & editing ZhangLiyuan 1 Writing – review & editing TanabeKenneth K. 1 Writing – review & editing WangXinhui 1 * Writing – original draft Writing – review & editing Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States Correspondence: Xinhui Wang, xwang30@mgh.harvard.edu

†These authors have contributed equally to this work and share first authorship

 18 02 2026 2026 16 1772315 20 12 2025 03 02 2026 28 12 2025 Copyright © 2026 Zhang, Wang, Fuchs, Guo, Drum, Erstad, Shi, DeLeo, Zheng, Cai, Zhang, Tanabe and Wang. 2026 Zhang, Wang, Fuchs, Guo, Drum, Erstad, Shi, DeLeo, Zheng, Cai, Zhang, Tanabe and Wang https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Improving the therapeutic efficacy of sorafenib for hepatocellular carcinoma by repurposing disulfiram By Zhang G, Wang Y, Fuchs BC, Guo W, Drum DL, Erstad DJ, Shi B, DeLeo AB, Zheng H, Cai L, Zhang L, Tanabe KK and Wang X (2022) Front. Oncol. 12:913736. doi: 10.3389/fonc.2022.913736 sorafenib disulfiram copper hepatic cancer stem cells ERK pathway section-at-acceptance Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

There was a mistake in Figure 2E as published. Some of the sphere images were unintentionally duplicated during the preparation process. The corrected Figure 2 and its caption appear below.

HCSCs are sensitive to DSF/Cu and sorafenib. The HCC cell lines HepG2 (A), Hep3B (B), SNU387 (C), and SNU423 (D) were treated as indicated, and ALDH+ cells was measured using flow cytometry. Sphere formation assays were performed in six-well plates by seeding treated cells and culturing for 14 days. Spheres were quantified by counting sphere numbers per well on day 14 (E, F). All experiments were performed in triplicate for each cell line, and data are shown as mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Microscopy image grid showing three generations of cell spheroids in four treatment groups: untreated, sorafenib, sorafenib with disulfiram (DSF), and sorafenib with DSF and copper (Cu). Spheroid numbers decrease with sorafenib and combination treatments across generations compared to untreated.

There was a mistake in Figure 6C as published. Some of the sphere images were unintentionally duplicated during the preparation process. The corrected Figure 6 and its caption appear below.

The sphere formation of cells isolated from the cells collected from xenograft tumors of each mouse group was assessed. Spheres were quantified by counting sphere numbers/well on day 14 (C, D).

Microscopy image grid displaying cell spheres across three generations and four conditions: untreated shows abundant, large spheres that increase with each generation; Sorafenib, Sorafenib plus disulfiram, and Sorafenib plus disulfiram with copper all show fewer and smaller spheres, with minimal changes between generations.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Edited and reviewed by: Sharon R Pine, University of Colorado Anschutz Medical Campus, United States